DECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1041 participants.

Also called NCT05276219

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,041 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05276219
  • EU CT 2022-500035-36-01
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05276219. Randomized; quadruple masking; primary purpose treatment. Start 2023-09-14 (actual); primary completion 2027-05-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
DECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure
Acronym
DECONGEST-AHF
Condition
Pulmonary Edema
Condition
Congestive Heart Failure
Condition
Acute Heart Failure
Intervention (Drug)
Furosemide Injection
Intervention (Drug)
Isosorbide Dinitrate
Intervention (Drug)
Furosemide and isosorbide dinitrate
Lead sponsor
Copenhagen University Hospital, Rigshospitalet (class: other)
Collaborator
Zealand University Hospital (class: other)
Collaborator
Copenhagen University Hospital, Hvidovre (class: other)
Collaborator
Herlev Hospital (class: other)
Collaborator
Bispebjerg Hospital (class: other)

Record details

Record id
cardio:ct-nct05276219
Content hash
21ea019692d3fa2608162ad36c93c2669f0583221256d91106009f84557fe7fc